RTTNews BiotechDoubao · 实盘不做把握 8/10不做原因:无增量信息
北京时间·🕒 发布 18:42:35·⟳ 抓取 18:45:21 +2m46s·⚡ 决策 10-26 18:46:41 +1m20s·1.5 天前
礼来在研KRAS G12C抑制剂olomorasib ESMO一线NSCLC早期数据：旧闻重报，三期数据2027H1才读出
本条RTTNews稿是对昨日(10-25 12:42/12:43 UTC)已处理的同一ESMO 2026 olomorasib更新的延迟重报：样本量、随访时间、PFS/DOR/ORR数字、2027H1三期时间点全部一致，无三期顶线、获批、合作或销售等任何新增事实；已处理记录的结论(议程内早期数据、超大市值无可交易弹性)仍然成立。
📄 原文RTTNews Biotech↗ 原文
Lilly Reports Olomorasib Results, Eyes First Phase 3 Data In H1 2027
Eli Lilly and Company (LLY) recently announced updated data from studies of investigational olomorasib, a next-generati…
不做 Eli Lilly and Company（LLY.US）
重复消息：同一ESMO 2026 olomorasib更新昨日(10-25)已由两源处理并判不做，本条为约22小时后RTTNews延迟重报、无任何新增事实；且属万亿市值公司未获批资产的早期单臂数据，关键3期2027H1才读出，无短期收入/估值增量，盘前仅+0.64%。等SUNRAY-01随机顶线或监管批准再评估。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
礼来olomorasib的ESMO早期NSCLC数据昨日已被两源研判为不做，本条RTTNews仅为约22小时后的同事实重报，无新增信息；资产未获批、关键三期2027H1才读出，对万亿市值礼来无短期增量，重复消息不再交易。
🔎 新鲜度:最早出现 2026-10-25 · 扩散 high · price-in 风险 high ↗
关键理由
- 数据本身正面但为单臂1/2期及3期安全性导入期随访更新，非注册性疗效读出
主要风险
- 真正可交易节点为SUNRAY-01随机3期顶线(2027H1)或监管批准，当前事件不构成入场edge
先例如何影响了这次决策
对本次决策的影响:确认重复消息不交易，维持AVOID
方向:本条因重复消息早停，不再新增先例研究；已处理记录已覆盖超大市值药企早期单臂数据无短线弹性的判断
涨幅量级:无可用于校准幅度的新增对齐先例；LLY盘前+0.64%本身已说明市场定价微弱
形态:议程内会议数据、会后媒体延迟重报通常无独立反应
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 234 ms
{"result": "search_processed_events:agent query=`eli lilly olomorasib kras g12c esmo 2026 nsclc sunray-01 | lly olomorasib pembrolizumab phase 1/2 loxo-ras-20001 sunray-01 results | 礼来 olomorasib kras g12c 抑制剂 一线 nsclc 数据`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 68.5/72 小时、2540 条本臂决策(完整)，返回 2 条候选。\n• 10-25 12:43 U
原文全文
展开原文 · 2,278 字
Eli Lilly and Company (LLY) recently announced updated data from studies of investigational olomorasib, a next-generation KRAS G12C inhibitor, in combination with immunotherapy, with or without chemotherapy, for first-line treatment of advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) at the ESMO Congress 2026.
In the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial, olomorasib plus pembrolizumab without chemotherapy showed durable activity across PD-L1 expression levels.
Among 85 patients, median progression-free survival (PFS) and duration of response (DOR) had not been reached after a median follow-up of 20.7 months.
In a separate analysis of 77 patients receiving olomorasib with pembrolizumab, pemetrexed and platinum chemotherapy, the confirmed overall response rate was 62%, median DOR was 14.5 months, and median PFS was 11.6 months after a median follow-up of 18.7 months.
The safety profiles were consistent with previous reports, with no Grade 5 treatment-related adverse events in either analysis. For the combination without chemotherapy, the most common Grade 3 or higher treatment-related adverse events included increased alanine aminotransferase, increased aspartate aminotransferase and diarrhea. With chemoimmunotherapy, the most common Grade 3 or higher events included neutropenia, anemia, increased alanine aminotransferase and thrombocytopenia.
Lilly said the findings support continued evaluation of olomorasib in the Phase 3 SUNRAY-01 program. The company expects the first randomized Phase 3 data in first-line KRAS G12C-mutant NSCLC in the first half of 2027.
Olomorasib is an investigational oral KRAS G12C inhibitor and has not been approved for any use.
LLY on Friday closed at $1,273, down 2.54%. In the pre-market trading, shares are up 0.64% at $1,282.40.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
In the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial, olomorasib plus pembrolizumab without chemotherapy showed durable activity across PD-L1 expression levels.
Among 85 patients, median progression-free survival (PFS) and duration of response (DOR) had not been reached after a median follow-up of 20.7 months.
In a separate analysis of 77 patients receiving olomorasib with pembrolizumab, pemetrexed and platinum chemotherapy, the confirmed overall response rate was 62%, median DOR was 14.5 months, and median PFS was 11.6 months after a median follow-up of 18.7 months.
The safety profiles were consistent with previous reports, with no Grade 5 treatment-related adverse events in either analysis. For the combination without chemotherapy, the most common Grade 3 or higher treatment-related adverse events included increased alanine aminotransferase, increased aspartate aminotransferase and diarrhea. With chemoimmunotherapy, the most common Grade 3 or higher events included neutropenia, anemia, increased alanine aminotransferase and thrombocytopenia.
Lilly said the findings support continued evaluation of olomorasib in the Phase 3 SUNRAY-01 program. The company expects the first randomized Phase 3 data in first-line KRAS G12C-mutant NSCLC in the first half of 2027.
Olomorasib is an investigational oral KRAS G12C inhibitor and has not been approved for any use.
LLY on Friday closed at $1,273, down 2.54%. In the pre-market trading, shares are up 0.64% at $1,282.40.
For comments and feedback contact: editorial@rttnews.com
Business News
October 16, 2026 16:06 ET Monthly consumer price inflation data and retail sales figures were the main news from the U.S. economy this week. In Europe, monthly GDP figures from the U.K. gained attention. External trade data from China was in focus in Asia. Elsewhere, the International Monetary Fund released its latest projections for the global economy.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
b10e9d9d3f· 2026-10-26 18:46 · doubao / doubao-seed-evolving-latest-version · 策略包b7b4acf827b8当前